Compare BOXL & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOXL | ARTL |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 2.6M |
| IPO Year | 2015 | N/A |
| Metric | BOXL | ARTL |
|---|---|---|
| Price | $3.25 | $0.78 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.1K | ★ 150.7K |
| Earning Date | 04-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,743,612.00 | N/A |
| Revenue This Year | $2.70 | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.37 | N/A |
| 52 Week Low | $0.50 | $0.71 |
| 52 Week High | $10.15 | $19.91 |
| Indicator | BOXL | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 27.41 |
| Support Level | $0.76 | N/A |
| Resistance Level | $5.19 | $1.87 |
| Average True Range (ATR) | 0.31 | 0.08 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 41.83 | 14.36 |
Boxlight Corp is a technology company that develops, sells, and services interactive solutions predominantly for the education market but also for the corporate and government sectors. The company currently designs, produces, and distributes interactive technologies, including interactive and non-interactive flat panel displays, LED video walls, media players, classroom audio and campus communication, cameras, and other peripherals for the education market and non-interactive solutions, including flat-panels, LED video walls, and digital signage for the enterprise market. It has three reportable segments - Europe, Middle East and Africa (EMEA), and North and Central America (Americas). The majority of revenue is derived from the sale of education technology products in the EMEA segment.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.